These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 20921460)

  • 1. Cancer vaccines in glioma: how to balance the challenges of small trials, efficiency, and potential adverse events.
    Lowenstein PR
    J Clin Oncol; 2010 Nov; 28(31):4670-3. PubMed ID: 20921460
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunologic escape after prolonged progression-free survival with epidermal growth factor receptor variant III peptide vaccination in patients with newly diagnosed glioblastoma.
    Sampson JH; Heimberger AB; Archer GE; Aldape KD; Friedman AH; Friedman HS; Gilbert MR; Herndon JE; McLendon RE; Mitchell DA; Reardon DA; Sawaya R; Schmittling RJ; Shi W; Vredenburgh JJ; Bigner DD
    J Clin Oncol; 2010 Nov; 28(31):4722-9. PubMed ID: 20921459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy for glioblastoma: the devil is in the details.
    Lesniak MS
    J Clin Oncol; 2011 Aug; 29(22):3105; author reply 3105-6. PubMed ID: 21709193
    [No Abstract]   [Full Text] [Related]  

  • 4. Dendritic cell immunotherapy for glioblastoma.
    Polyzoidis S; Ashkan K
    Expert Rev Anticancer Ther; 2014 Jul; 14(7):761-3. PubMed ID: 24850137
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting EGF receptor variant III: tumor-specific peptide vaccination for malignant gliomas.
    Del Vecchio CA; Li G; Wong AJ
    Expert Rev Vaccines; 2012 Feb; 11(2):133-44. PubMed ID: 22309662
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Peptide vaccination in glioblastoma].
    Terasaki M; Morioka M
    Gan To Kagaku Ryoho; 2014 Jun; 41(6):725-9. PubMed ID: 25167577
    [No Abstract]   [Full Text] [Related]  

  • 7. Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma.
    Maxwell R; Jackson CM; Lim M
    Curr Treat Options Oncol; 2017 Aug; 18(8):51. PubMed ID: 28785997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rindopepimut with temozolomide for patients with newly diagnosed, EGFRvIII-expressing glioblastoma (ACT IV): a randomised, double-blind, international phase 3 trial.
    Weller M; Butowski N; Tran DD; Recht LD; Lim M; Hirte H; Ashby L; Mechtler L; Goldlust SA; Iwamoto F; Drappatz J; O'Rourke DM; Wong M; Hamilton MG; Finocchiaro G; Perry J; Wick W; Green J; He Y; Turner CD; Yellin MJ; Keler T; Davis TA; Stupp R; Sampson JH;
    Lancet Oncol; 2017 Oct; 18(10):1373-1385. PubMed ID: 28844499
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early-stage progress on glioma vaccines.
    Brower V
    J Natl Cancer Inst; 2011 Sep; 103(18):1361-2. PubMed ID: 21881038
    [No Abstract]   [Full Text] [Related]  

  • 10. The value of EGFRvIII as the target for glioma vaccines.
    Lowenstein PR; Castro MG
    Am Soc Clin Oncol Educ Book; 2014; ():42-50. PubMed ID: 24857059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy offers a promising bet against brain cancer.
    Eisenstein M
    Nature; 2018 Sep; 561(7724):S42-S44. PubMed ID: 30258155
    [No Abstract]   [Full Text] [Related]  

  • 12. Anti-epidermal growth factor receptor therapy for glioblastoma in adults.
    Lee A; Arasaratnam M; Chan DLH; Khasraw M; Howell VM; Wheeler H
    Cochrane Database Syst Rev; 2020 May; 5(5):CD013238. PubMed ID: 32395825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled phase II trial of vaccination with lysate-loaded, mature dendritic cells integrated into standard radiochemotherapy of newly diagnosed glioblastoma (GlioVax): study protocol for a randomized controlled trial.
    Rapp M; Grauer OM; Kamp M; Sevens N; Zotz N; Sabel M; Sorg RV
    Trials; 2018 May; 19(1):293. PubMed ID: 29801515
    [TBL] [Abstract][Full Text] [Related]  

  • 14. EGFRvIII-targeted vaccination therapy of malignant glioma.
    Choi BD; Archer GE; Mitchell DA; Heimberger AB; McLendon RE; Bigner DD; Sampson JH
    Brain Pathol; 2009 Oct; 19(4):713-23. PubMed ID: 19744042
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination.
    Wheeler CJ; Das A; Liu G; Yu JS; Black KL
    Clin Cancer Res; 2004 Aug; 10(16):5316-26. PubMed ID: 15328167
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Immunotherapeutics for Treatment of Glioblastoma: The Last Decade of Research.
    Khansur E; Shah AH; Lacy K; Komotar RJ
    Cancer Invest; 2019; 37(1):1-7. PubMed ID: 30632816
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic Immunization against Glioblastoma.
    Schijns VEJC; Pretto C; Strik AM; Gloudemans-Rijkers R; Deviller L; Pierre D; Chung J; Dandekar M; Carrillo JA; Kong XT; Fu BD; Hsu FPK; Hofman FM; Chen TC; Zidovetzki R; Bota DA; Stathopoulos A
    Int J Mol Sci; 2018 Aug; 19(9):. PubMed ID: 30150597
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccine for aggressive brain tumors may prolong survival.
    Health News; 2004 Dec; 10(12):7. PubMed ID: 15645564
    [No Abstract]   [Full Text] [Related]  

  • 19. Epidermal growth factor receptor vaccination for glioblastoma multiforme.
    Komotar RJ; Starke RM; Connolly ES; Sisti MB
    Neurosurgery; 2011 Feb; 68(2):N20-1. PubMed ID: 21654573
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: case study.
    Heimberger AB; Sun W; Hussain SF; Dey M; Crutcher L; Aldape K; Gilbert M; Hassenbusch SJ; Sawaya R; Schmittling B; Archer GE; Mitchell DA; Bigner DD; Sampson JH
    Neuro Oncol; 2008 Feb; 10(1):98-103. PubMed ID: 18079360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.